← Leaderboards
Antonio Di Cristofano
Albert Einstein College Of Medicine
$12,865,971
Attributed
$12,865,971
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,865,971 · 5
By mechanism
R01$10,223,664 · 3
P50$2,642,307 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Incidence”
- Lawrence Corey · Fred Hutchinson Cancer Center$280,538,218
- David M Nathan · Massachusetts Institute Of Technology$138,375,637
- Sharon A Nachman · Johns Hopkins University$135,132,510
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$127,753,192
- James E. Gern · University Of Wisconsin-Madison$123,967,847
- John M Lachin · George Washington University$118,672,444
Research focus
IncidenceMolecularMutationPathway InteractionsSignal TransductionIn VivoThyroid GlandTumorCellsMalignant Neoplasm Of ThyroidBaseGeneticMediatingProto-Oncogene Proteins C-AktDesignMalignant NeoplasmsOncogenicIn Vivo ModelGrowthIn VitroWomanNeoplastic Cell TransformationHyperplasiaPten Gene
Grant awards (41)
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$401,385
R01 · FY2024 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$422,510
R01 · FY2023 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$414,060
R01 · FY2022 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$422,510
R01 · FY2021 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$422,510
R01 · FY2020 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$321,896
R01 · FY2019 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$62,204
R01 · FY2019 · CA · contact PI
Molecular Landscape-based Innovative Therapies for Anaplastic Thyroid Carcinoma$542,931
P50 · FY2018 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$396,625
R01 · FY2018 · CA · contact PI
Molecular Landscape-based Innovative Therapies for Anaplastic Thyroid Carcinoma$520,414
P50 · FY2017 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$396,625
R01 · FY2017 · CA · contact PI
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid$346,525
R01 · FY2017 · CA · contact PI
Molecular Landscape-based Innovative Therapies for Anaplastic Thyroid Carcinoma$518,583
P50 · FY2016 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$396,625
R01 · FY2016 · CA · contact PI
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid$346,525
R01 · FY2016 · CA · contact PI
Molecular Landscape-based Innovative Therapies for Anaplastic Thyroid Carcinoma$529,155
P50 · FY2015 · CA · contact PI
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid$247,942
R01 · FY2015 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$226,758
R01 · FY2015 · CA · contact PI
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer$169,867
R01 · FY2015 · CA · contact PI
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid$98,583
R01 · FY2015 · CA · contact PI
Molecular Landscape-based Innovative Therapies for Anaplastic Thyroid Carcinoma$531,224
P50 · FY2014 · CA · contact PI
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid$336,129
R01 · FY2014 · CA · contact PI
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease$102,705
R01 · FY2014 · CA · contact PI
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid$346,525
R01 · FY2013 · CA · contact PI
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease$314,070
R01 · FY2013 · CA · contact PI
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease$334,117
R01 · FY2012 · CA · contact PI
PTEN and the molecular genetics of endometrial cancer$314,583
R01 · FY2012 · CA · contact PI
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease$334,117
R01 · FY2011 · CA · contact PI
PTEN and the molecular genetics of endometrial cancer$1
R01 · FY2011 · CA · contact PI
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease$344,450
R01 · FY2010 · CA · contact PI
PTEN and the molecular genetics of endometrial cancer$334,341
R01 · FY2010 · CA · contact PI
Genetic analysis of the P13K/Akt pathway in thyroid benign and malignant disease$344,450
R01 · FY2009 · CA · contact PI
PTEN and the molecular genetics of endometrial cancer$334,341
R01 · FY2009 · CA · contact PI
PTEN and the molecular genetics of endometrial cancer$344,347
R01 · FY2008 · CA · contact PI
PTEN and the Molecular Genetics of Endometrial Cancer$330,469
R01 · FY2006 · CA · contact PI
PTEN and the Molecular Genetics of Endometrial Cancer$338,757
R01 · FY2005 · CA
PTEN and the Molecular Genetics of Endometrial Cancer$340,425
R01 · FY2004 · CA
PTEN and the Molecular Genetics of Endometrial Cancer$336,687
R01 · FY2003 · CA
CORE--ANIMAL MODELS$0
P50 · FY2002 · CA
CORE--ANIMAL MODELS$0
P50 · FY2002 · CA
CORE--ANIMAL MODELS$0
P50 · FY2001 · CA